|
1
|
Antoni S, Ferlay J, Soerjomataram I, Znaor
A, Jemal A and Bray F: Bladder cancer incidence and mortality: A
global overview and recent trends. Eur Urol. 71:96–108.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mohammadian M, Safari A, Bakeshei KA, Asti
A, Mohammadian-Hafshejani A, Salehiniya H, Emamiyan M and Khakpour
H: Recent patterns of bladder cancer incidence and mortality: A
global overview. World Cancer Res J. 7(e1464)2020.
|
|
3
|
Dy GW, Gore JL, Forouzanfar MH, Naghavi M
and Fitzmaurice C: Global burden of urologic cancers, 1990-2013.
Eur Urol. 71:437–446. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cumberbatch MGK, Jubber I, Black PC,
Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K,
Silverman DT, et al: Epidemiology of bladder cancer: A systematic
review and contemporary update of risk factors in 2018. Eur Urol.
74:784–795. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chamie K, Litwin MS, Bassett JC, Daskivich
TJ, Lai J, Hanley JM, Konety BR and Saigal CS: Urologic Diseases in
America Project. Recurrence of high-risk bladder cancer: A
population-based analysis. Cancer. 119:3219–3227. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Picozzi S, Ricci C, Gaeta M, Ratti D,
Macchi A, Casellato S, Bozzini G and Carmignani L: Upper urinary
tract recurrence following radical cystectomy for bladder cancer: A
meta-analysis on 13,185 patients. J Urol. 188:2046–2054.
2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Mariotto AB, Robin Yabroff K, Shao Y,
Feuer EJ and Brown ML: Projections of the cost of cancer care in
the United States: 2010-2020. J Natl Cancer Inst. 103:117–128.
2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jocham D, Stepp H and Waidelich R:
Photodynamic diagnosis in urology: State-of-the-art. Eur Urol.
53:1138–1150. 2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sutton AJ, Lamont JV, Evans R, Williamson
K, O'Rourke D, Duggan B, Sagoo GS, Reid CN and Ruddock MW: An early
analysis of the cost-effectiveness of a diagnostic classifier for
risk stratification of haematuria patients (DCRSHP) compared to
flexible cystoscopy in the diagnosis of bladder cancer. PLoS One.
13(e0202796)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Glatz K, Willi N, Glatz D, Barascud A,
Grilli B, Herzog M, Dalquen P, Feichter G, Gasser TC, Sulser T and
Bubendorf L: An international telecytologic quiz on urinary
cytology reveals educational deficits and absence of a commonly
used classification system. Am J Clin Pathol. 126:294–301.
2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Biardeau X, Lam O, Ba V, Campeau L and
Corcos J: Prospective evaluation of anxiety, pain, and
embarrassment associated with cystoscopy and urodynamic testing in
clinical practice. J Can Urol Assoc. 11:104–110. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Burke DM, Shackley DC and O'Reilly PH: The
community-based morbidity of flexible cystoscopy. BJU Int.
89:347–349. 2002.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lotan Y and Roehrborn CG: Sensitivity and
specificity of commonly available bladder tumor markers versus
cytology: Results of a comprehensive literature review and
meta-analyses. Urology. 61:109–118. 2003.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Raitanen MP, Aine R, Rintala E, Kallio J,
Rajala P, Juusela H and Tammela TLJ: Differences between local and
review urinary cytology in diagnosis of bladder cancer. An
interobserver multicenter analysis. Eur Urol. 41:284–289.
2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Jung A and Kirchner T: Liquid biopsy in
tumor genetic diagnosis. Dtsch Arztebl Int. 115:169–174.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rothé F, Laes JF, Lambrechts D, Smeets D,
Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C,
et al: Plasma circulating tumor DNA as an alternative to metastatic
biopsies for mutational analysis in breast cancer. Ann Oncol.
25:1959–1965. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Millholland JM, Li S, Fernandez CA and
Shuber AP: Detection of low frequency FGFR3 mutations in the urine
of bladder cancer patients using next-generation deep sequencing.
Res reports Urol. 4:33–40. 2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Pan W, Gu W, Nagpal S, Gephart MH and
Quake SR: Brain tumor mutations detected in cerebral spinal fluid.
Clin Chem. 61:514–522. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Liang Y, Han J, Jia C, Ma Y, Lan Y, Li Y
and Wang S: Effect of endometrial injury on secretion of
endometrial cytokines and IVF outcomes in women with unexplained
subfertility. Mediators Inflamm. 2015(757184)2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Arneth B: Update on the types and usage of
liquid biopsies in the clinical setting: A systematic review. BMC
Cancer. 18(527)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mathai R, Vidya R, Reddy B, Thomas L,
Udupa K, Kolesar J and Rao M: Potential utility of liquid biopsy as
a diagnostic and prognostic tool for the assessment of solid
tumors: Implications in the precision oncology. J Clin Med.
8(373)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Remon J, García-Campelo R, de Álava E,
Vera R, Rodríguez-Peralto JL, Rodríguez-Lescure Á, Bellosillo B,
Garrido P, Rojo F and Álvarez-Alegret R: Liquid biopsy in oncology:
A consensus statement of the spanish society of pathology and the
spanish society of medical oncology. Clin Transl Oncol. 22:823–834.
2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chen M and Zhao H: Next-generation
sequencing in liquid biopsy: Cancer screening and early detection.
Hum Genomics. 13(34)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ou Z, Li K, Yang T, Dai Y, Chandra M, Ning
J, Wang Y, Xu R, Gao T, Xie Y, et al: Detection of bladder cancer
using urinary cell-free DNA and cellular DNA. Clin Transl Med.
9(4)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Avogbe PH, Manel A, Vian E, Durand G,
Forey N, Voegele C, Zvereva M, Hosen MI, Meziani S, De Tilly B, et
al: Urinary TERT promoter mutations as non-invasive biomarkers for
the comprehensive detection of urothelial cancer. EBioMedicine.
44:431–438. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lodewijk I, Dueñas M, Rubio C,
Munera-Maravilla E, Segovia C, Bernardini A, Teijeira A, Paramio JM
and Suárez-Cabrera C: Liquid biopsy biomarkers in bladder cancer: A
current need for patient diagnosis and monitoring. Int J Mol Sci.
19(2514)2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang K, Liu T, Liu C, Meng Y, Yuan X, Liu
L, Ge N, Liu J, Wang C, Ren H, et al: TERT promoter mutations and
TERT mRNA but Not FGFR3 mutations are urinary biomarkers in han
chinese patients with urothelial bladder cancer. Oncologist.
20:263–269. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yuan X, Liu C, Wang K, Liu L, Liu T, Ge N,
Kong F, Yang L, Björkholm M, Fan Y, et al: The genetic difference
between Western and Chinese urothelial cell carcinomas: Infrequent
FGFR3 mutation in Han Chinese patients. Oncotarget. 7:25826–25835.
2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Stepanov VA, Balanovsky OP, Melnikov AV,
Lash-Zavada AY, Khar'kov VN, Tyazhelova TV, Akhmetova VL, Zhukova
OV, Shneider YV, Shil'nikova IN, et al: Characteristics of
populations of the russian federation over the panel of fifteen
loci used for DNA identification and in forensic medical
examination. Acta Naturae. 3:56–67. 2011.PubMed/NCBI
|
|
30
|
Zhernakova DV, Brukhin V, Malov S, Oleksyk
TK, Koepfli KP, Zhuk A, Dobrynin P, Kliver S, Cherkasov N, Tamazian
G, et al: Genome-wide sequence analyses of ethnic populations
across Russia. Genomics. 112:442–458. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hayashi Y, Fujita K, Matsuzaki K,
Matsushita M, Kawamura N, Koh Y, Nakano K, Wang C, Ishizuya Y,
Yamamoto Y, et al: Diagnostic potential of TERT promoter and FGFR3
mutations in urinary cell-free DNA in upper tract urothelial
carcinoma. Cancer Sci. 110:1771–1779. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Russo IJ, Ju Y, Gordon NS, Zeegers MP,
Cheng KK, James ND, Bryan R and Ward DG: Toward personalised liquid
biopsies for urothelial carcinoma: Characterisation of ddPCR and
urinary cfDNA for the detection of the TERT 228 G>A/T mutation.
Bladder Cancer. 4:41–48. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Siraj AK, Bu R, Iqbal K, Parvathareddy SK,
Siraj N, Siraj S, Diaz MRF, Rala DR, Benito AD, Sabido MA, et al:
Telomerase reverse transcriptase promoter mutations in cancers
derived from multiple organ sites among middle eastern population.
Genomics. 112:1746–1753. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Demaree B, Weisgerber D, Dolatmoradi A,
Hatori M and Abate AR: Direct quantification of EGFR variant allele
frequency in cell-free DNA using a microfluidic-free digital
droplet PCR assay. Methods Cell Biol. 148:119–131. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Crimi S, Falzone L, Gattuso G, Grillo CM,
Candido S, Bianchi A and Libra M: Droplet digital PCR analysis of
liquid biopsy samples unveils the diagnostic role of
hsa-miR-133a-3p and hsa-miR-375-3p in oral cancer. Biology (Basel).
9(379)2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Falzone L, Musso N, Gattuso G, Bongiorno
D, Palermo CI, Scalia G, Libra M and Stefani S: Sensitivity
assessment of droplet digital PCR for SARS-CoV-2 detection. Int J
Mol Med. 46:957–964. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
La Rocca F, Grieco V, Ruggieri V, Zifarone
E, Villani O, Zoppoli P, Russi S, Laurino S, Falco G, Calice G, et
al: Superiority of droplet digital PCR over real-time quantitative
PCR for JAK2 V617F allele mutational burden assessment in
myeloproliferative neoplasms: A retrospective study. Diagnostics
(Basel). 10(143)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hosen MI, Forey N, Durand G, Voegele C,
Bilici S, Avogbe PH, Delhomme TM, Foll M, Manel A, Vian E, et al:
Development of sensitive droplet digital PCR assays for detecting
urinary TERT promoter mutations as non-invasive biomarkers for
detection of urothelial cancer. Cancers (Basel).
12(3541)2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Mao X, Liu C, Tong H, Chen Y and Liu K:
Principles of digital PCR and its applications in current
obstetrical and gynecological diseases. Am J Transl Res.
11:7209–7222. 2019.PubMed/NCBI
|
|
40
|
Zhang H, Liu R, Yan C, Liu L, Tong Z,
Jiang W, Yao M, Fang W and Chen Z: Advantage of next-generation
sequencing in dynamic monitoring of circulating tumor DNA over
droplet digital PCR in cetuximab treated colorectal cancer
patients. Transl Oncol. 12:426–431. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Ruiz-Villalba A, van Pelt-Verkuil E, Gunst
QD, Ruijter JM and van den Hoff MJ: Amplification of nonspecific
products in quantitative polymerase chain reactions (qPCR). Biomol
Detect Quantif. 14:7–18. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Tate JG, Bamford S, Jubb HC, Sondka Z,
Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E,
et al: COSMIC: The catalogue of somatic mutations in cancer.
Nucleic Acids Res. 47:D941–D947. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Tomczak K, Czerwińska P and Wiznerowicz M:
The Cancer Genome Atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Horn S, Figl A, Rachakonda PS, Fischer C,
Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al:
TERT promoter mutations in familial and sporadic melanoma. Science.
339:959–961. 2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin
L and Garraway LA: Highly recurrent TERT promoter mutations in
human melanoma. Science. 339:957–959. 2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Ward DG, Baxter L, Gordon NS, Ott S,
Savage RS, Beggs AD, James JD, Lickiss J, Green S, Wallis Y, et al:
Multiplex PCR and next generation sequencing for the non-invasive
detection of bladder cancer. PLoS One. 11(e0149756)2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Critelli R, Fasanelli F, Oderda M,
Polidoro S, Assumma MB, Viberti C, Preto M, Gontero P, Cucchiarale
G, Lurkin I, et al: Detection of multiple mutations in urinary
exfoliated cells from male bladder cancer patients at diagnosis and
during follow-up. Oncotarget. 7:67435–67448. 2016.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Batista R, Lima L, Vinagre J, Pinto V,
Lyra J, Máximo V, Santos L and Soares P: TERT promoter mutation as
a potential predictive biomarker in BCG-treated bladder cancer
patients. Int J Mol Sci. 21(947)2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Borah S, Xi L, Zaug AJ, Powell NM, Dancik
GM, Cohen SB, Costello JC, Theodorescu D and Cech TR: Cancer. TERT
promoter mutations and telomerase reactivation in urothelial
cancer. Science. 347:1006–1010. 2015.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Li Y, Zhou QL, Sun W, Chandrasekharan P,
Cheng HS, Ying Z, Lakshmanan M, Raju A, Tenen DG, Cheng SY, et al:
Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T
mutant TERT promoter activation. Nat Cell Biol. 17:1327–1338.
2015.PubMed/NCBI View Article : Google Scholar
|
|
51
|
van Kessel KEM, Beukers W, Lurkin I,
Ziel-van der Made A, van der Keur KA, Boormans JL, Dyrskjøt L,
Márquez M, Ørntoft TF, Real FX, et al: Validation of a DNA
methylation-mutation urine assay to select patients with hematuria
for cystoscopy. J Urol. 197:590–595. 2017.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Wu S, Ou T, Xing N, Lu J, Wan S, Wang C,
Zhang X, Yang F, Huang Y and Cai Z: Whole-genome sequencing
identifies ADGRG6 enhancer mutations and FRS2 duplications as
angiogenesis-related drivers in bladder cancer. Nat Commun.
10(720)2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wang W, Kong P, Ma G, Li L, Zhu J, Xia T,
Xie H, Zhou W and Wang S: Characterization of the release and
biological significance of cell-free DNA from breast cancer cell
lines. Oncotarget. 8:43180–43191. 2017.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Aucamp J, Bronkhorst AJ, Peters DL, Van
Dyk HC, Van der Westhuizen FH and Pretorius PJ: Kinetic analysis,
size profiling, and bioenergetic association of DNA released by
selected cell lines in vitro. Cell Mol Life Sci. 74:2689–2707.
2017.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Bronkhorst AJ, Ungerer V and Holdenrieder
S: The emerging role of cell-free DNA as a molecular marker for
cancer management. Biomol Detect Quantif. 17(100087)2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6(224ra24)2014.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Abbosh C, Birkbak NJ, Wilson GA,
Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA,
Veeriah S, Rosenthal R, et al: Phylogenetic ctDNA analysis depicts
early-stage lung cancer evolution. Nature. 545:446–451.
2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Parkinson CA, Gale D, Piskorz AM, Biggs H,
Hodgkin C, Addley H, Freeman S, Moyle P, Sala E, Sayal K, et al:
Exploratory analysis of TP53 mutations in circulating tumour DNA as
biomarkers of treatment response for patients with relapsed
high-grade serous ovarian carcinoma: A retrospective study. PLoS
Med. 13(e1002198)2016.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Leão R, Lee D, Figueiredo A, Hermanns T,
Wild P, Komosa M, Lau I, Mistry M, Nunes NM, Price AJ, et al:
Combined genetic and epigenetic alterations of the TERT promoter
affect clinical and biological behavior of bladder cancer. Int J
Cancer. 144:1676–1684. 2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Hosen MI, Sheikh M, Zvereva M, Scelo G,
Forey N, Durand G, Voegele C, Poustchi H, Khoshnia M, Roshandel G,
et al: Urinary TERT promoter mutations are detectable up to 10
years prior to clinical diagnosis of bladder cancer: Evidence from
the Golestan Cohort Study. EBioMedicine. 53(102643)2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Birkenkamp-Demtröder K, Christensen E,
Nordentoft I, Knudsen M, Taber A, Høyer S, Lamy P, Agerbæk M,
Jensen JB and Dyrskjøt L: Monitoring treatment response and
metastatic relapse in advanced bladder cancer by liquid biopsy
analysis. Eur Urol. 73:535–540. 2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Vinagre J, Almeida A, Pópulo H, Batista R,
Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al:
Frequency of TERT promoter mutations in human cancers. Nat Commun.
4(2185)2013.PubMed/NCBI View Article : Google Scholar
|
